 The primary objective in this study is to collect post-marketing information on Riociguat safety.Thus, the information on adverse events AEs and adverse drug reactions ADRs that occur within the first 12 months and in the following 6 -year observation at most, after starting Riociguat treatment under the routine clinical practice will be collected. 